← FDA DRUG APPROVALS

FDA ANDA · ANDA206005

DAPTOMYCIN

Sponsor: XELLIA PHARMS APS

APPLICATION
ANDA206005
TYPE
ANDA
ORIGINAL APPROVAL
2016-06-15
LATEST ACTION
2020-09-09
ROUTE
INTRAVENOUS
DOSAGE FORM
POWDER
MARKETING STATUS
Prescription

Products

DAPTOMYCINPrescription
DAPTOMYCIN 500MG/VIAL · POWDER · INTRAVENOUS

Approval history

2020-09-09Labeling · Supplement 19 · standardAP
2020-09-09Labeling · Supplement 17 · standardAP
2019-10-03Labeling · Supplement 14 · standardAP
2019-10-03Labeling · Supplement 6 · standardAP
2019-10-03Labeling · Supplement 11 · standardAP
2016-12-21Labeling · Supplement 1 · standardAP
2016-06-15UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →